Ginkgo Bioworks Q3: Revenue Down, Loss Narrows as Restructuring Cuts Take Hold; New Lab System Customers Highlighted

What happened

Ginkgo Bioworks reported lower third-quarter revenue versus the prior year, reflecting ongoing weakness in Biosecurity and only modest growth in Cell Engineering services. The net loss narrowed as restructuring-related expense reductions took hold, with management emphasizing the benefits of prior cost actions and facility consolidation into Biofab1. Executives highlighted new customers for the company's autonomous laboratory systems and cloud-based lab services, suggesting progress in shifting toward more productized, recurring revenue streams. However, the revenue decline underscores that the company has not yet stabilized its top line, and the improved bottom line is primarily driven by cost cuts rather than organic growth. With cash and equivalents having fallen to $251 million as of mid-2025 and ongoing negative free cash flow, Ginkgo's liquidity runway remains a critical concern unless revenue growth accelerates.

Implication

Investors should monitor whether new customer wins for autonomous lab systems and cloud services translate into meaningful revenue growth and improved gross margins. The narrowing loss is encouraging but not yet sufficient to ensure self-sustainability. With limited cash and uncertain revenue trajectory, the stock likely remains range-bound until there is clearer evidence of revenue stabilization or additional financing.

Thesis delta

The Q3 update reinforces the ongoing restructuring and pivot to fee-for-service, with no dramatic change from our previous HOLD thesis. The new customer announcements are a modest positive signal that the productized lab systems and cloud services are gaining commercialization traction. However, the continued revenue decline and unresolved liquidity concerns prevent any upgrade at this time.